title: Rest and exercise cardiovascular effects of terazosin in congestive heart failure.
abstract: This study investigated the acute effects of the alpha 1 antagonist terazosin on myocardial circulatory responses at rest and during exercise. Ten patients with congestive heart failure (class III and IV) underwent hemodynamic evaluation before and after a 5-mg oral dose of terazosin. At rest and during exercise, terazosin significantly decreased pulmonary capillary wedge pressure, systemic vascular resistance and mean arterial pressure while cardiac index increased. Stroke volume index increased (p less than 0.01) during exercise while left ventricular stroke work index remained unchanged in both experimental conditions. Terazosin administration significantly decreased both rest and exercise myocardial oxygen consumption while exercise coronary sinus oxygen content increased and arterial-coronary sinus oxygen difference diminished (p less than 0.05). Parallel with these changes, alpha blockade decreased the ratio of coronary blood flow to total cardiac output. Coronary vascular resistance remained unaltered with alpha blockade both at rest and during exercise. Coronary blood flow tended to diminish with decreased myocardial oxygen demand. Alpha 1 blockade induces systemic vasodilation and improves myocardial circulatory parameters without inducing coronary dilation or altering metabolic autoregulation.
authors.affiliation: Department of Medicine (Cardiovascular Division), Ohio State University, Columbus.
authors.forename: R D
authors.initials: RD
authors.lastname: Magorien
authors.forename: S
authors.initials: S
authors.lastname: Sinnathamby
authors.forename: C V
authors.initials: CV
authors.lastname: Leier
authors.forename: H
authors.initials: H
authors.lastname: Boudoulas
authors.forename: D V
authors.initials: DV
authors.lastname: Unverferth
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D003326:Coronary Circulation / Q000187:drug effects; D015444:Exercise / Q000502:physiology; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012146:Rest / Q000502:physiology
chemical_list: D000317:Adrenergic alpha-Antagonists; C041226:Terazosin; D011224:Prazosin